Hye Won Lee

Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD.

Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD.

A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study.

Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement

Chronic Hepatitis B Infection: Patient Guidance.

Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm.

Correspondence to editorial on "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease".

Steatosis-Associated Fibrosis Estimator Score in Asian Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.

Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery.

Integration of <i>PNPLA3</i> and <i>TM6SF2</i> genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus.

Fibrotic MASH resolution<sup>VCTE</sup> index to diagnose fibrotic MASH resolution and predict LREs: A global multicenter study.

Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Precision Public Health Risk Stratification for Hepatocellular Carcinoma in Non-Cirrhotic MASLD: Development and Validation Across Asian and Western Cohorts

Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease

Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease

Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut–liver axis

From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease.

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025.

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.

Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis.

Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic Perspective.

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease.

AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment.

Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD

Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance: A Randomized, Single-Center Trial.